final program final program 21st erasmus Liver Day 21st erasmus ...

09.30
09.40 - 10.00
10.00 - 10.20
10.20 - 10.40
10.40 - 11.00
11.00 - 11.30
11.30 - 11.50
11.50 - 12.10
12.10 - 12.30
12.30 - 13.30
13.30 - 13.40
13.40 - 14.00
14.00 - 14.20
14.20 - 14.40
14.40 - 15.00
15.00 - 15.30
15.30 - 15.50
15.50 - 16.10
16.10 - 16.30
16.30
18.00
Program
Welcome and introduction of interactive system H.L.A. Janssen
Biliary diseases Chairman G. Kazemier
Mayo Clinic experience with liver transplantation in
cholangiocarcinoma J.K. Heimbach
Endoscopic photodynamic therapy for cholangiocarcinoma E.A.J. Rauws
Autoimmune Pancreatico-cholangitis: diagnosis
and treatment H.R. van Buuren
Case R.A. de Man
Coffee break
Portal hypertension Chairman H.L.A. Janssen
Diagnostic work-up and treatment of portal vein trombosis D.C. Valla
Long-term results of endoscopic treatment of gastro-esophageal
bleeding in portal vein trombosis V.M.C.W. Spaander
Case P.B.F. Mensink
Lunch
Metabolic liver disease Chairman J.H.P. Wilson
Interaction H.R. van Buuren
Hemochromatosis: consensus and clinical guidelines R.A. de Vries
Alcoholic hepatitis: new classification system with therapeutic
implications E.H. Forrest
Hepatitis C Chairman S.W. Schalm
Optimal duration of antiviral treatment for hepatitis C R.J. de Knegt
Antiviral effect of cyclosporine in hepatitis C: mechanism and
potential use H.J. Metselaar
Tea break
Hepatitis B Chairman E.J. Kuipers
How and when to use entecavir and other new antivirals
in hepatitis B R.A. de Man
Therapeutic implications of hepatitis B genotype testing H.L.A. Janssen
Reliability of Fibroscan fibrosis assessment in hepatitis B
and other liver diseases C. Verveer
Closure & drinks H.R. van Buuren
R.A. de Man
Post AASLD symposium